Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 billion. On the other hand, the company’s full-year revenue guidance of $62.5 ...

We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

In summary, income-focused investors may find Pfizer stock an attractive option for making a steady income of $100 per month ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more about PFE stock here.

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals ...

BioNTech SE (BNTX) reports a net profit for Q4 2024 amidst a challenging year, with strategic advancements in oncology and ...